AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 23 min read$MIRM

Peetz Christopher sold $88K of MIRM

Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 883 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $99.66 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peetz Christopher
Published Jun 2, 2026, 11:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MIRM
Neutral
medium confidence
Mentioned
$MIRM
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMNeutralLow
01

Why it matters

Insider sales can influence short-term sentiment, but 10b5-1 plans are designed to reduce timing-based trading signals.

02

Market read

A single disclosed insider sale at a stated price; likely sentiment-neutral with limited trading edge.

03

What to watch

The sale size is modest relative to typical institutional float; without additional context (e.g., multiple concurrent insider actions), the signal is likely limited.

Relevance 4/10Novelty 3/10Timing: Filed June 2; transaction executed June 1.

Background

The filing is an SEC Form 4 insider transaction by Mirum Pharmaceuticals’ CEO, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MIRMNeutralMedium confidence
Context

Mirum Pharmaceuticals CEO Christopher Peetz sold $87,999.78 of MIRM stock via an open-market transaction under a 10b5-1 plan on June 1.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

Form 4 provides a specific sale price/size and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider sales can still coincide with management’s near-term liquidity needs or reduced conviction, potentially capping upside.

Key entities

  • issuer
    Mirum Pharmaceuticals, Inc.

    Subject of the insider transaction disclosure (Form 4).

  • insider
    Peetz Christopher

    CEO who sold 883 shares at $99.6600 on June 1 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$MIRMMed

Mirum Pharmaceuticals, Inc. (MIRM): Results of Operations and Financial Condition

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mirm-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 millio

SEC EDGAR 8-K6 min
JUN 4
$MIRMMedAI 9/10

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

The article is largely promotional and does not provide verifiable details of Mirum Pharmaceuticals’ Phase 2b results for volixibat in PSC. It references an “EASL Congress” update but includes no specific efficacy/safety figures. It also promotes subscription offers and claims about prior stock-pick performance and “upside potential,” without citing sources.

insidermonkey.com6 min
MAY 30
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals (Nasdaq: MIRM) presented late-breaking Phase 2b data at EASL 2026. In PSC, volixibat reduced cholestatic pruritus by 2.72 points (placebo-adjusted -1.64; p<0.0001) with 56% vs 26% achieving ≥2-point itch reduction. In HDV, brelovitug met a Week-24 endpoint in 45%/35% vs 0% (delayed). In PFIC, LIVMARLI improved event-free survival vs NAPPED (HR 0.29).

finanznachrichten.de6 min
MAY 25
$MIRMMedAI 8/10

Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)

Simply Wall St discusses Mirum Pharmaceuticals (MIRM) and notes the company’s potential US$600 million zero-coupon convertible note issuance, saying it could affect the investment case. The piece frames “rewards” and “warning signs” based on historical data and analyst forecasts, and cautions it is general information, not financial advice.

finance.yahoo.com4 min